AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

An Investigation Into Dielectric Testing for the Evaluation and Characterisation of Breast Tissue Using a Novel Time-Domain Bioimpedance Tool

Recruitingn/aAges 18 Years - 85 YearsFemaleZedsen Limited
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Capacitance measures a material's ability to store the movement of electrical energy in the electric field. Different of the human body are known to have different capacitance values. Research is looking into utilising capacitance differences, using a method called bioimpedance, to detect signatures of cancer. Breast cancer is the most common type of cancer in women globally, and the bioimpedance of healthy breast tissue is different to cancer tissue. Breast tissue is accessible by non-invasive means and has well-established clinical tools for cancer detection. However, results from studies vary and research is needed to understand how bioimpedance can be used in cancer research and the development of less invasive detection tools. Zedsen Limited developed the time-domain bioimpedance sensing (TD-BIS) scanner capable of measuring capacitance. Previous versions of the TD-BIS scanner were

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Attending a breast clinic appointment or other appointment at a participating site * Assigned female sex at time of birth * Aged 18 years or older at time of scan * Willing, able and mentally competent to read, understand, and provide informed consent in English * Patients who wish to enter the NACT sub-study, inclusion in NACT care is required. Exclusion Criteria: * Participants who have undergone biopsy less than 14 days before the TD-BIS scanner session * Participants with implanted electronics anywhere in the body * Participants with breast implants * Participants with nipple piercings (unless they are removed prior to the scan) * Participants who are lactating * Pregnant participants by verbal confirmation * Participants with pacemakers * Participants with open breast wound * Participants who had previous breast surgery (mastectomy, lumpectomy) * Participants who have breast lesion localisation device (i.e., wire, seed, Magseed) \*Patients who wish to enter the NACT sub-study, there is one additional exclusion criteria: * Participants who have any breast surgery prior to the second scan
๐Ÿ’Š

What it tests

  • TD-BIS scanner
๐Ÿ“

Where

1 site
Imperial College Trust
London, United Kingdom
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy